Amendments to the claims:

This listing of claims replaces all prior versions, and listings, of claims in the application.

Listing of claims:

1 (currently amended): A pharmaceutical composition comprising at least one TGF-beta antagonist, selected from the group consisting of

- oligonucleotides hybridising with an area of the messenger RNA ~~(=RNA)~~ (mRNA) and/or DNA encoding TGF-beta, wherein the oligonucleotide comprises at least one of the sequences of SEQ ID NO: 1-78,
- TGF-beta receptors and/or parts of them binding TGF-beta,
- proteins, except antibodies, inhibiting TGF-beta
- peptides of less than 100 kDa inhibiting TGF-beta
- peptides being parts of TGF-beta

and at least one substance inhibiting cell proliferation and/or inducing cell death[,] selected from the group consisting of temozolomide, nitrosoureas, Vinca alkaloids, antagonists of the purine and pyrimidine bases, cytostatic active antibiotics, caphthotecine derivatives, anti-androgens, anti-estrogens, ~~anti-progesterons~~ anti-progesterones and analogs of gonadotropin releasing hormone.

2 (original): The pharmaceutical composition of claim 1 wherein the at least one TGF-beta antagonist and the at least one substance inhibiting cell proliferation and/or inducing cell death are mixed together.

3 (original): The pharmaceutical composition of claim 1 wherein the at least one TGF-beta antagonist and the at least one substance inhibiting cell proliferation and/or inducing cell death are separate.

4 (cancelled).

5 (currently amended): The pharmaceutical composition according to claim ~~4~~ 1 wherein at least one nucleotide of the oligonucleotide is modified at the sugar moiety, the base and/or the internucleotide linkage.

6 (original): The pharmaceutical composition according to claim 5 wherein at least one modified internucleotide linkage is a phosphorothioate linkage.

7 (currently amended): The pharmaceutical composition according to claim 1 wherein

- the nitrosourea is selected from the group of ACNU, BCNU and CCNU,

- the Vinca-~~alcaloid~~ alkaloid is selected from the group consisting of vinblastine, vincristine, and vindesine,
- the antagonist of the purine and pyrimidine bases is selected from the group consisting of ~~5-fluorouracile~~ 5-fluorouracil, 5-fluorodeoxiuridine, cytarabine and gemcitabine,
- the cytostatic antibiotic is selected from the group consisting of ~~doxorubicine~~ doxorubicin and liposomal PEGylated doxorubicin,
- the camphthotecine derivative is selected from the group consisting of irinotecane and topotecane,
- the anti ~~estrogenes~~ estrogens are selected from the group consisting of tamoxifen, exemestane, anastrozole and fulvestrant,
- the antiandrogens are selected from the group consisting of flutamide and bicalutamide,
- the ~~antiprogesterons~~ anti-progesterones are selected from the group consisting of ~~mifepriston~~ mifepristone, and
- the analogs of gonadotropin releasing ~~hormon~~ hormone are selected from the group consisting of leuprolide and gosereline.

Claims 8-17 (canceled).

18 (previously presented): Method of treating a neoplasm comprising the step of administering the composition of claim 1 and optionally the step of applying radiation to a patient in need thereof.

19 (canceled).

20 (previously presented): Method of treating a neoplasm according to claim 18 wherein the neoplasm is selected from the group of: bile duct carcinoma, bladder carcinoma, brain tumor, breast carcinoma, bronchogenic carcinoma, carcinoma of the kidney, cervical carcinoma, choriocarcinoma, cystadenocarcinome, embrional carcinoma, epithelial carcinoma, esophageal carcinoma, cervical carcinoma, colon carcinoma, colorectal carcinoma, endometrial carcinoma, gallbladder carcinoma, gastric carcinoma, head carcinoma, liver carcinoma, lung carcinoma, medullary carcinoma, neck carcinoma, non-small-cell bronchogenic/lung carcinoma, ovarian carcinoma, pancreas carcinoma, papillary carcinoma, papillary adenocarcinoma, prostata carcinoma, small intestine carcinoma, prostate carcinoma, rectal carcinoma, renal cell carcinoma, skin carcinoma, small-cell bronchogenic/lung carcinoma, squamous cell carcinoma, sebaceous gland carcinoma, testicular carcinoma, uterine carcinoma, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; pre-malignant tumors; rheumatoid arthritis; psoriasis; astracytoma, acoustic neuroma, blastoma, Ewing´s tumor, astracytoma, craniopharyngloma, ependymoma, medulloblastoma, glioma, hemangloblastoma, Hodgkins-lymphoma, medullablastoma, leukaemia, mesothelioma, neuroblastoma, neurofibroma, non-Hodgkins lymphoma, pinealoma, retinoblastoma, retinoblastoma, sarcoma (including angiosarcoma, chondrosarcoma, endothelialsarcoma, fibrosarcoma, leiomyosarcoma, liposarcoma, lymphangioandotheliosarcoma, lyphangiosarcoma, melanoma,

meningioma, myosarcoma, oligodendroglioma, osteogenic sarcoma, osteosarcoma), seminoma, trachomas, Wilm's tumor.

21 (previously presented): Method of treating a neoplasm according to claim 18 wherein the step of administering a pharmaceutical composition occurs before or after the step of applying radiation.

22 (previously presented): Method of treating a neoplasm according to claim 18 wherein the step of administering a pharmaceutical composition occurs together with the step of applying radiation.

23 (previously presented): Method of treating a neoplasm according to claim 21 wherein the total amount of radiation within one cycle is from about 10 Gy to about 100 Gy.

24 (previously presented): Method of treating a neoplasm according to claim 23 wherein the total amount of radiation of one cycle is applied by several fractions from of about 1 Gy to about 2 Gy.

Claims 25-28 (cancelled).